These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26133710)

  • 1. Population Pharmacokinetics in China: The Dynamics of Intravenous Voriconazole in Critically Ill Patients with Pulmonary Disease.
    Chen W; Xie H; Liang F; Meng D; Rui J; Yin X; Zhang T; Xiao X; Cai S; Liu X; Li Y
    Biol Pharm Bull; 2015; 38(7):996-1004. PubMed ID: 26133710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
    Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
    PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
    Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
    Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
    Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y
    Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
    Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
    Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients.
    Aoyama T; Hirata K; Hirata R; Yamazaki H; Yamamoto Y; Hayashi H; Matsumoto Y
    J Clin Pharm Ther; 2012 Jun; 37(3):356-63. PubMed ID: 21883330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
    Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
    Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
    Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
    Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis.
    Ren QX; Li XG; Mu JS; Bi JF; Du CH; Wang YH; Zhu H; Lv P; Zhao QG
    J Pharm Sci; 2019 Dec; 108(12):3923-3931. PubMed ID: 31562869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Voriconazole in Peritoneal Fluid of Critically Ill Patients.
    Lin XB; Hu XG; Tang ZX; Guo PH; Liu XM; Liang T; Xia YZ; Lui KY; Chen P; Tang KJ; Chen X; Cai CJ
    Antimicrob Agents Chemother; 2023 May; 67(5):e0172122. PubMed ID: 37022169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of voriconazole plasma concentrations on treatment response in critically ill patients.
    Ruiz J; Gordon M; Villarreal E; Peruccioni M; Marqués MR; Poveda-Andrés JL; Castellanos-Ortega Á; Ramirez P
    J Clin Pharm Ther; 2019 Aug; 44(4):572-578. PubMed ID: 30851209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study.
    Elkayal O; Mertens B; Wauters J; Debaveye Y; Rijnders B; Verweij PE; Brüggemann RJ; Spriet I; Dreesen E
    J Antimicrob Chemother; 2024 Jul; 79(7):1645-1656. PubMed ID: 38828958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.